Chronic Kidney Disease
Renal 6 original drugsMarket Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 54 industry trials with a known mechanism of action.
SGLT2
5 trials 1 active 3 sponsors
Sodium-Glucose Cotransporter 2 Inhibitor
5 trials 1 active 2 sponsors
CaSR
4 trials 1 active 1 sponsor
Parenteral Iron Replacement
3 trials 1 active 1 sponsor
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
2 trials 1 active 1 sponsor
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
14 trials 1 sponsor
Vitamin D2 Analog
6 trials 3 sponsors
Erythropoiesis-stimulating Agent
5 trials 2 sponsors
ferric reductase/phosphate
4 trials 2 sponsors
Erythropoietin Receptor
2 trials 2 sponsors
GLP-1 Receptor Agonist
2 trials 2 sponsors
Kinase Inhibitor
2 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
531 industry-sponsored trials across 179 sponsors
Showing 30 of 30 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Ace Cells Lab Limited | ACE Reno | — | RECRUITING | 2026-08-31 | NCT07187713 |
| Zydus Lifesciences Limited | Desidustat | — | RECRUITING | 2025-06-30 | NCT05515367 |
| AstraZeneca | Dapagliflozin | SGLT2 | ACTIVE NOT RECRUITING | 2027-05-31 | NCT06610526 |
| Xuanzhu Biopharmaceutical Co., Ltd. | Anaprazole Sodium enteric-coated tablet | — | NOT YET RECRUITING | 2026-10-30 | NCT07345689 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | Enarodustat 2mg | — | NOT YET RECRUITING | 2027-06 | NCT07079579 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | ganagliflozin | — | NOT YET RECRUITING | 2031-10-30 | NCT07116928 |
| Bayer | Finerenone (Kerendia, BAY94-8862) | — | COMPLETED | 2025-07-03 | NCT05705271 |
| AstraZeneca | Sodium Zirconium Cyclosilicate (SZC) | — | COMPLETED | 2024-12-10 | NCT05347693 |
| Ardelyx | Tenapanor | — | COMPLETED | 2021-10-13 | NCT04549597 |
| AstraZeneca | Roxadustat | — | COMPLETED | 2021-10-12 | NCT04655027 |
| Keryx Biopharmaceuticals | KRX-0502 | — | COMPLETED | 2019-08-30 | NCT03236246 |
| Sumitomo Pharma (Suzhou) Co., Ltd. | Arotinolol Hydrochloride | — | COMPLETED | 2018-10-10 | NCT01351636 |
| Novartis | Induction therapy | — | COMPLETED | 2017-02-01 | NCT01950819 |
| Amgen | Epoetin alfa | Erythropoietin Receptor | COMPLETED | 2016-04-27 | NCT02253654 |
| AbbVie (prior sponsor, Abbott) | Paricalcitol | Vitamin D2 Analog [EPC] | COMPLETED | 2016-04-07 | NCT01506947 |
| AMAG Pharmaceuticals, Inc. | Ferumoxytol | Parenteral Iron Replacement [EPC] | COMPLETED | 2016-02 | NCT01227616 |
| Yuhan Corporation | Anplag(Sarpogrelate) | — | COMPLETED | 2014-11-17 | NCT01869881 |
| Fresenius Medical Care Korea | — | — | COMPLETED | 2014-04 | NCT01997385 |
| GE Healthcare | Omniscan | Paramagnetic Contrast Agent [EPC] | COMPLETED | 2013-06 | NCT00908310 |
| Otsuka Beijing Research Institute | Probucol | — | COMPLETED | 2012-12 | NCT01252056 |
| Fresenius Medical Care North America | Calcium acetate oral solution (COS) | — | COMPLETED | 2012-07 | NCT01427907 |
| Guerbet | Dotarem®-enhanced MRI | — | COMPLETED | 2011-05 | NCT00650845 |
| Abbott | Paricalcitol | Vitamin D2 Analog [EPC] | COMPLETED | 2011-05 | NCT00977080 |
| Novo Nordisk | — | — | COMPLETED | 2011-04 | NCT01245374 |
| Amgen | Cinacalcet | — | COMPLETED | 2010-12-09 | NCT00803712 |
| Abbott | Zemplar (paricalcitol) | — | COMPLETED | 2010-09 | NCT00891813 |
| Novartis | HX575 recombinant human erythropoietin alfa | — | COMPLETED | 2010-03 | NCT00632125 |
| Ironwood Pharmaceuticals, Inc. | Lesinurad | — | TERMINATED | 2019-02-25 | NCT03226899 |
| GE Healthcare | Visipaque | — | TERMINATED | 2018-09-13 | NCT03119662 |
| B. Braun Melsungen AG | HES 130/0.42 + electrolyte solution | — | TERMINATED | 2010-09 | NCT00936247 |
Showing 100 of 163 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Alebund Pharmaceuticals | AP301 | — | RECRUITING | 2026-06-20 | NCT06933472 |
| AMAG Pharmaceuticals, Inc. | Ferumoxytol | Parenteral Iron Replacement [EPC] | RECRUITING | 2026-08-31 | NCT03619850 |
| Kind Pharmaceuticals LLC | AND017 capsules | — | RECRUITING | 2026-10-30 | NCT07494409 |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | MT1013 | — | RECRUITING | 2026-11-26 | NCT07122401 |
| Genexine, Inc. | Efepoetin Alfa | — | RECRUITING | 2026-12 | NCT06466785 |
| Kind Pharmaceuticals LLC | AND017 | — | RECRUITING | 2026-12-01 | NCT07487727 |
| Renibus Therapeutics, Inc. | Veverimer | — | RECRUITING | 2027-06 | NCT07355062 |
| Bayer | Finerenone (Kerendia, BAY94-8862) | — | RECRUITING | 2027-07-31 | NCT05196035 |
| Astellas Pharma Global Development, Inc. | Roxadustat | — | RECRUITING | 2027-10-30 | NCT05970172 |
| Boehringer Ingelheim | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | RECRUITING | 2028-06-26 | NCT07107945 |
| Bayer | Finerenone (Kerendia, BAY94-8862) | — | RECRUITING | 2029-01-28 | NCT05457283 |
| Amgen | Etelcalcetide | CaSR | RECRUITING | 2029-01-31 | NCT03633708 |
| Prokidney | Renal Autologous Cell Therapy (REACT/ rilparencel) | — | RECRUITING | 2029-12 | NCT05099770 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-1780 tablets | — | RECRUITING | 2030-04 | NCT07419828 |
| Eli Lilly | Orforglipron | — | RECRUITING | 2031-08 | NCT07241390 |
| Biocad | BCD-131 (pegdarbepoetin beta) | — | RECRUITING | 2026-05 | NCT07119372 |
| Novo Nordisk | Ziltivekimab B | — | ACTIVE NOT RECRUITING | 2026-06-09 | NCT05021835 |
| Akebia Therapeutics | Erythropoiesis-Stimulating Agent (ESA) | — | ACTIVE NOT RECRUITING | 2026-08 | NCT06901505 |
| AstraZeneca | Zibotentan/Dapagliflozin | — | ACTIVE NOT RECRUITING | 2027-02-18 | NCT06087835 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2029-02 | NCT06383390 |
| AstraZeneca | Ravulizumab | — | ACTIVE NOT RECRUITING | 2026-05-18 | NCT05746559 |
| Daewoong Pharmaceutical Co. LTD. | DWP16001 0.3mg | — | NOT YET RECRUITING | 2026-09-01 | NCT06606093 |
| Ebima Clifford Okundaye | QRX-3 | — | NOT YET RECRUITING | 2026-10 | NCT06866236 |
| Megalabs | Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration. | — | NOT YET RECRUITING | 2027-03 | NCT06352138 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2026-03-16 | NCT05803421 |
| Bayer | Finerenone (BAY94-8862) | — | COMPLETED | 2025-12-31 | NCT05047263 |
| Vifor Fresenius Medical Care Renal Pharma | Patiromer Powder for Oral Suspension (Part A) | — | COMPLETED | 2025-11-18 | NCT05136664 |
| Bayer | Finerenone | Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC] | COMPLETED | 2025-08-20 | NCT05901831 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-11-21 | NCT04865770 |
| Alebund Pharmaceuticals | AP301 | — | COMPLETED | 2024-10-02 | NCT07030595 |
| Serodus AS | SER150 | — | COMPLETED | 2024-06-06 | NCT04881123 |
| Galderma R&D | Nemolizumab | — | COMPLETED | 2024-01-04 | NCT05075408 |
| MediBeacon | MB-102 | — | COMPLETED | 2023-02-15 | NCT05425719 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2023-01-06 | NCT04707768 |
| Nanogen Pharmaceutical Biotechnology Joint Stock Company | Stimus (NNG-DEPO) | — | COMPLETED | 2022-11-23 | NCT05585645 |
| Panion & BF Biotech Inc. | Ferric citrate | ferric reductase/phosphate | COMPLETED | 2022-10-28 | NCT04543812 |
| Boehringer Ingelheim | Empagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2022-07-05 | NCT03594110 |
| PT Kalbe Genexine Biologics | efepoetin alfa | — | COMPLETED | 2022-03-30 | NCT04155125 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | SAL-0951 | — | COMPLETED | 2021-10-08 | NCT06016036 |
| Zydus Lifesciences Limited | Desidustat Oral Tablet | — | COMPLETED | 2021-09-02 | NCT04215120 |
| Zydus Lifesciences Limited | Desidustat Oral Tablet | — | COMPLETED | 2021-08-25 | NCT04012957 |
| Bio Sidus SA | Erythropoietin alfa | — | COMPLETED | 2021-06-15 | NCT04036253 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pegol-Sihematide | — | COMPLETED | 2021-02-28 | NCT03902691 |
| JW Pharmaceutical | JTZ-951 | — | COMPLETED | 2021-02-23 | NCT04027517 |
| Bayer | Finerenone (BAY94-8862) | — | COMPLETED | 2021-02-02 | NCT02545049 |
| Tanabe Pharma Corporation | Canagliflozin | SGLT2 | COMPLETED | 2021-01-21 | NCT03436693 |
| Vifor Fresenius Medical Care Renal Pharma | PA21 | — | COMPLETED | 2020-08-21 | NCT03644264 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2020-06-18 | NCT02680574 |
| AstraZeneca | Dapagliflozin | SGLT2 | COMPLETED | 2020-06-12 | NCT03036150 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2020-06-04 | NCT02648347 |
| Bayer | Finerenone (BAY94-8862) | — | COMPLETED | 2020-04-14 | NCT02540993 |
| Amgen | Etelcalcetide | CaSR | COMPLETED | 2020-04-08 | NCT03299244 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2020-01-31 | NCT02865850 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2020-01-16 | NCT02892149 |
| Boryung Pharmaceutical Co., Ltd | Fimsartan 60mg~120mg | — | COMPLETED | 2019-12-23 | NCT02620306 |
| Astellas Pharma Inc | roxadustat | — | COMPLETED | 2019-09-13 | NCT02988973 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2019-08-07 | NCT03543657 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2019-07-25 | NCT03418168 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2019-07-05 | NCT03350347 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2019-05-17 | NCT03350321 |
| Lexicon Pharmaceuticals | Sotagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2019-05-16 | NCT03242018 |
| Lexicon Pharmaceuticals | Sotagliflozin | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | COMPLETED | 2019-03-25 | NCT03242252 |
| Tanabe Pharma Corporation | MT-6548 | — | COMPLETED | 2019-01-08 | NCT03329196 |
| Tanabe Pharma Corporation | MT-6548 | — | COMPLETED | 2018-12-12 | NCT03439137 |
| Tanabe Pharma Corporation | MT-6548 | — | COMPLETED | 2018-12-03 | NCT03461146 |
| Tanabe Pharma Corporation | MT-6548 | — | COMPLETED | 2018-11-22 | NCT03402386 |
| Johnson & Johnson | Canagliflozin | SGLT2 | COMPLETED | 2018-10-30 | NCT02065791 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2018-10-23 | NCT03351166 |
| Astellas Pharma Inc | roxadustat | — | COMPLETED | 2018-08-15 | NCT02964936 |
| Pharmacosmos A/S | Iron isomaltoside/ferric derisomaltose | — | COMPLETED | 2018-05-29 | NCT02940860 |
| Astellas Pharma Europe B.V. | Roxadustat | — | COMPLETED | 2018-03-23 | NCT02021318 |
| Astellas Pharma Inc | roxadustat | — | COMPLETED | 2018-03-13 | NCT02952092 |
| Proteon Therapeutics | Vonapanitase | — | COMPLETED | 2018-02 | NCT02414841 |
| Shield Therapeutics | Ferric maltol | — | COMPLETED | 2018-01-18 | NCT02968368 |
| Astellas Pharma Inc | roxadustat | — | COMPLETED | 2017-12-12 | NCT02780141 |
| Astellas Pharma Europe B.V. | Roxadustat | — | COMPLETED | 2017-11-01 | NCT01887600 |
| Amgen | Darbepoetin alfa | Erythropoiesis-stimulating Agent [EPC] | COMPLETED | 2017-10-19 | NCT01652872 |
| Astellas Pharma Inc | roxadustat | — | COMPLETED | 2017-08-02 | NCT02780726 |
| Chong Kun Dang Pharmaceutical | CKD-11101 | — | COMPLETED | 2017-06 | NCT03428594 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Tolvaptan (OPC-41061) | — | COMPLETED | 2017-04-18 | NCT02160145 |
| Amgen | Cinacalcet | — | COMPLETED | 2017-03-15 | NCT02341417 |
| Chong Kun Dang Pharmaceutical | CKD-11101(Darbepoetin alfa) | — | COMPLETED | 2017-02 | NCT03431623 |
| Biocad | Darbepoetin alfa | Erythropoiesis-stimulating Agent [EPC] | COMPLETED | 2017-01-08 | NCT02506868 |
| Proteon Therapeutics | PRT-201 | — | COMPLETED | 2016-12 | NCT02110901 |
| Pfizer | Epoetin Hospira Arm | — | COMPLETED | 2016-07-02 | NCT02504294 |
| Eli Lilly | Dulaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2016-06 | NCT01621178 |
| Keryx Biopharmaceuticals | ferric citrate | ferric reductase/phosphate | COMPLETED | 2016-01 | NCT02268994 |
| Novartis | Valsartan | Angiotensin 2 Receptor Blocker [EPC] | COMPLETED | 2015-09 | NCT01365481 |
| OPKO Health, Inc. | CTAP101 Capsules | — | COMPLETED | 2015-05 | NCT02282813 |
| Fresenius Medical Care Deutschland GmbH | Osvaren Granules | — | COMPLETED | 2015-04 | NCT02027662 |
| Astellas Pharma Inc | ASP1585 | — | COMPLETED | 2015-04 | NCT01742611 |
| Amgen | Etelcalcetide | CaSR | COMPLETED | 2014-11-12 | NCT01896232 |
| Novartis | HX575 epoetin alfa (Sandoz) | — | COMPLETED | 2014-10 | NCT01576341 |
| OPKO IP Holdings II, Inc. | CTAP101 30 μg capsules | — | COMPLETED | 2014-08 | NCT01704079 |
| OPKO IP Holdings II, Inc. | CTAP101 30 μg capsules | — | COMPLETED | 2014-07 | NCT01651000 |
| Pharmacosmos A/S | Monofer | — | COMPLETED | 2014-06 | NCT01102413 |
| AbbVie (prior sponsor, Abbott) | Paricalcitol | Vitamin D2 Analog [EPC] | COMPLETED | 2014-05 | NCT01020487 |
| Novartis | HX575 epoetin alfa | — | COMPLETED | 2014-05 | NCT01693029 |
| Astellas Pharma Inc | ASP1585 | — | COMPLETED | 2014-05 | NCT01742585 |
| Pfizer | Epoetin Hospira | — | COMPLETED | 2014-02-28 | NCT01473420 |
Showing 100 of 177 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| AstraZeneca | Zibotentan/Dapagliflozin | — | RECRUITING | 2026-07-31 | NCT06942910 |
| Novo Nordisk | NNC0519-0130 | — | RECRUITING | 2026-09-01 | NCT06717698 |
| Ingenia Therapeutics INC | IGT-303 | — | RECRUITING | 2026-10 | NCT07231679 |
| River 3 Renal Corp. | R3R01 | — | RECRUITING | 2026-10 | NCT06600412 |
| AION Healthspan, Inc. | AION-301 | — | RECRUITING | 2027-01 | NCT06721143 |
| PT. Prodia Stem Cell Indonesia | Umbilical Cord Mesenchymal Stem Cells | — | RECRUITING | 2027-07 | NCT07396155 |
| Regeneron | ALN-ANG3 | — | RECRUITING | 2027-09-24 | NCT07271186 |
| Regeneron | Vonsetamig | — | RECRUITING | 2027-11-22 | NCT05092347 |
| Vifor Fresenius Medical Care Renal Pharma | Difelikefalin | — | RECRUITING | 2029-08-15 | NCT06593392 |
| The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 | — | RECRUITING | 2030-07-11 | NCT07134335 |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | MT1013 | — | RECRUITING | 2025-08-19 | NCT06976177 |
| Boehringer Ingelheim | Vicadrostat | — | ACTIVE NOT RECRUITING | 2026-08-20 | NCT06926660 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-09 | NCT05536804 |
| Biocity Biopharmaceutics Co., Ltd. | SC0062 low dose | — | ACTIVE NOT RECRUITING | 2024-11-30 | NCT05687890 |
| PT. JES Kasih Nusantara Sejahterah | Dendritic cell immunotherapy | — | ACTIVE NOT RECRUITING | 2024-08-05 | NCT06866158 |
| Novartis | Atrasentan | — | ACTIVE NOT RECRUITING | 2024-07-02 | NCT04573920 |
| R1 Therapeutics | AP306 75 mg BID | — | NOT YET RECRUITING | 2027-02-28 | NCT06712654 |
| Atom Therapeutics Co., Ltd | ABP-671 plus febuxostat Group 1 | — | NOT YET RECRUITING | 2027-10-31 | NCT07323095 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-10390 | — | NOT YET RECRUITING | 2027-11-11 | NCT07555054 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR6508 | — | COMPLETED | 2025-11-13 | NCT06236295 |
| Bayer | BAY3283142 | — | COMPLETED | 2025-10-24 | NCT06522997 |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | MT1013 | — | COMPLETED | 2025-10-15 | NCT06690242 |
| Eli Lilly | Retatrutide | — | COMPLETED | 2025-10-01 | NCT05936151 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-09-24 | NCT06131372 |
| Revelation Biosciences, Inc | Intravenous Gemini | — | COMPLETED | 2025-07-22 | NCT06863467 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2025-05-20 | NCT05018416 |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Long-term Dosing Cohort | — | COMPLETED | 2025-05-12 | NCT06747247 |
| AstraZeneca | Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg | — | COMPLETED | 2025-05-09 | NCT06350123 |
| Bayer | Finerenone (BAY94-8862 ) 10 mg | — | COMPLETED | 2025-03-14 | NCT05254002 |
| Tourmaline Bio, Inc. | TOUR006 - 50 MG | — | COMPLETED | 2025-03-06 | NCT06362759 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo | — | COMPLETED | 2025-03-05 | NCT06221059 |
| Mineralys Therapeutics Inc. | Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD | — | COMPLETED | 2025-02-27 | NCT06150924 |
| Shanghai Pharmaceuticals Holding Co., Ltd | SPH3127+SPH3127matching placebo+valsartan matching placebo | — | COMPLETED | 2024-12-31 | NCT05593575 |
| Ebima Clifford Okundaye | QRX-3 | — | COMPLETED | 2024-08-30 | NCT06948292 |
| Inversago Pharma Inc. | INV-202 | — | COMPLETED | 2024-08-20 | NCT05514548 |
| Unicycive Therapeutics, Inc | Oxylanthanum Carbonate | — | COMPLETED | 2024-05-29 | NCT06218290 |
| AstraZeneca | CIN-107 | — | COMPLETED | 2024-05-02 | NCT05432167 |
| MC2 Therapeutics | MC2-25 cream | — | COMPLETED | 2024-02-02 | NCT05482698 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2023-12 | NCT02836574 |
| Neurocrine UK Limited | Chronocort | — | COMPLETED | 2023-10-18 | NCT05222152 |
| AstraZeneca | AZD9977 | — | COMPLETED | 2023-09-22 | NCT04595370 |
| Alebund Pharmaceuticals | AP-306 | — | COMPLETED | 2023-08-25 | NCT05764590 |
| Boehringer Ingelheim | Avenciguat | — | COMPLETED | 2023-08-15 | NCT04736628 |
| AstraZeneca | Zibotentan | — | COMPLETED | 2023-06-01 | NCT04724837 |
| AstraZeneca | MEDI3506 | — | COMPLETED | 2023-05-16 | NCT04170543 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2022-11-17 | NCT03270956 |
| CSL Behring | CSL346 | — | COMPLETED | 2022-10-24 | NCT04419467 |
| AstraZeneca | Cotadutide 100 micrograms | — | COMPLETED | 2022-03-08 | NCT04515849 |
| Bayer | runcaciguat | — | COMPLETED | 2022-03-08 | NCT04507061 |
| Allena Pharmaceuticals | ALLN-346 | — | COMPLETED | 2022-03-02 | NCT04987242 |
| Xiamen Amoytop Biotech Co., Ltd. | YPEG-rhEPO | — | COMPLETED | 2022-01-05 | NCT04885647 |
| Bayer | Finerenone (Kerendia, BAY94-8862) | — | COMPLETED | 2021-12-31 | NCT05013008 |
| AstraZeneca | Verinurad | — | COMPLETED | 2021-11-22 | NCT03990363 |
| Biogen | Bardoxolone methyl oral capsule | — | COMPLETED | 2021-10-20 | NCT04702997 |
| Gilead | SEL | — | COMPLETED | 2021-09-03 | NCT04026165 |
| Novo Nordisk | Ziltivekimab | — | COMPLETED | 2021-08-03 | NCT04626505 |
| Roche | Mircera | Erythropoietin Receptor | COMPLETED | 2021-07-19 | NCT03552393 |
| Novartis | Nidufexor | — | COMPLETED | 2021-05-03 | NCT03804879 |
| KBP Biosciences | KBP-5074 0.25 mg tablet | — | COMPLETED | 2020-08-05 | NCT03574363 |
| Dimerix Bioscience Pty Ltd | Propagermanium | — | COMPLETED | 2020-07-23 | NCT03627715 |
| Novo Nordisk | Ziltivekimab | — | COMPLETED | 2020-06-26 | NCT03926117 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2020-06-05 | NCT03799627 |
| Kyntra Bio | Roxadustat | — | COMPLETED | 2019-12-12 | NCT01630889 |
| Cara Therapeutics, Inc. | CR845 0.25 mg Oral Tablet | — | COMPLETED | 2019-10-24 | NCT03617536 |
| Bayer | Fulacimstat (BAY1142524) | — | COMPLETED | 2019-10-02 | NCT03412006 |
| Teijin America, Inc. | TMX-049 | — | COMPLETED | 2019-05-07 | NCT03449199 |
| UnicoCell Biomed CO. LTD | ELIXCYTE | — | COMPLETED | 2019-04-23 | NCT02933827 |
| Pieris Pharmaceuticals GmbH | PRS-080#022-DP | — | COMPLETED | 2019-03-30 | NCT03325621 |
| MedImmune LLC | MEDI0382 | — | COMPLETED | 2019-02-04 | NCT03550378 |
| Takeda | Lanthanum Carbonate | — | COMPLETED | 2018-11-16 | NCT01696279 |
| Novartis | LHW090 | — | COMPLETED | 2018-10-11 | NCT02678000 |
| Fresenius Kabi | Ketosteril® | — | COMPLETED | 2018-04-27 | NCT03077048 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2017-10-24 | NCT03054350 |
| Tanabe Pharma Corporation | MT-3995 Low | — | COMPLETED | 2017-08 | NCT02676401 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2017-07-04 | NCT03054337 |
| Genexine, Inc. | GX-E2 | — | COMPLETED | 2017-04-20 | NCT02044653 |
| Vascular Pharmaceuticals, Inc. | VPI-2690B low dose | — | COMPLETED | 2017-03 | NCT02251067 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2016-11-15 | NCT02055482 |
| Tanabe Pharma Corporation | MT-3995 Low | — | COMPLETED | 2016-11 | NCT02517320 |
| Astellas Pharma Europe B.V. | ASP8232 | — | COMPLETED | 2016-10-26 | NCT02358096 |
| Bayer | Molidustat (BAY85-3934) | — | COMPLETED | 2016-10-19 | NCT02064426 |
| Gilead | Selonsertib | — | COMPLETED | 2016-07 | NCT02177786 |
| Aevi Genomic Medicine, LLC, a Cerecor company | MDGN201 TARGTEPO | — | COMPLETED | 2016-06-30 | NCT02117427 |
| Daiichi Sankyo | CS-3150 | — | COMPLETED | 2016-06 | NCT02345057 |
| 3-C Institute for Social Development | — | — | COMPLETED | 2016-06 | NCT02864641 |
| Kyowa Kirin Co., Ltd. | RTA 402 | — | COMPLETED | 2016-05 | NCT02316821 |
| La Jolla Pharmaceutical Company | GCS-100 | — | COMPLETED | 2016-05 | NCT02155673 |
| Capricor Inc. | Cenderitide | — | COMPLETED | 2016-03-31 | NCT02603614 |
| Mallinckrodt | Repository Corticotropin Injection | — | COMPLETED | 2016-01 | NCT01601236 |
| Bayer | Molidustat (BAY 85-3934) | — | COMPLETED | 2015-10-23 | NCT01975818 |
| Bayer | BAY85-3934 | — | COMPLETED | 2015-10-15 | NCT02021409 |
| Bayer | BAY85-3934 | — | COMPLETED | 2015-09-15 | NCT02021370 |
| Eli Lilly | LY3016859 | — | COMPLETED | 2015-08 | NCT01774981 |
| Tanabe Pharma Corporation | MT-3995 | — | COMPLETED | 2015-08 | NCT02205372 |
| Astellas Pharma Inc | ASP1517 | — | COMPLETED | 2015-07-06 | NCT01964196 |
| AstraZeneca | Eculizumab | Complement Inhibitor [EPC] | COMPLETED | 2015-06-11 | NCT01567085 |
| Genzyme, a Sanofi Company | Sevelamer carbonate | — | COMPLETED | 2015-06 | NCT01574326 |
| Ardelyx | AZD1722 | — | COMPLETED | 2015-03 | NCT01847092 |
| Hansa Biopharma AB | IdeS | — | COMPLETED | 2015-02 | NCT02224820 |
| Concert Pharmaceuticals | CTP-499 | — | COMPLETED | 2015-01 | NCT01487109 |
Showing 100 of 161 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| AstraZeneca | AZD4248 | — | RECRUITING | 2026-06-18 | NCT07024823 |
| Beijing Continent Pharmaceutical Co, Ltd. | Hydronidone capsules | — | RECRUITING | 2026-07-01 | NCT07262333 |
| Eli Lilly | LY3841136 | — | RECRUITING | 2026-10 | NCT07426380 |
| Mediar Therapeutics | MTX-439 | — | RECRUITING | 2027-05 | NCT07473323 |
| Novartis | OJR520 | — | RECRUITING | 2028-01-21 | NCT07235059 |
| Alebund Pharmaceuticals | AP303 150μg | — | RECRUITING | 2025-09-25 | NCT06666283 |
| Henan Genuine Biotech Co., Ltd. | Azvudine tablets | — | RECRUITING | 2025-08-30 | NCT07001436 |
| Consun Pharmaceutical Group | SK-08 | — | RECRUITING | 2025-08-07 | NCT07021157 |
| Shandong Suncadia Medicine Co., Ltd. | [14C]HRS-1780 | — | NOT YET RECRUITING | 2026-06 | NCT07557407 |
| Klotho Sciences Australia Pty Ltd. | Part 1 KS101 | — | NOT YET RECRUITING | 2026-04-01 | NCT07143331 |
| R3 Stem Cell | Amniotic and Umbilical Cord Tissue Procedure | — | NOT YET RECRUITING | 2024-03-20 | NCT03899298 |
| Eli Lilly | LY3537031 | — | COMPLETED | 2026-04-16 | NCT07165015 |
| Eli Lilly | LY3537982 | — | COMPLETED | 2026-04-10 | NCT07137689 |
| Bayer | BAY3283142 | — | COMPLETED | 2025-11-21 | NCT06428825 |
| Novo Nordisk | NNC0705-0001 | — | COMPLETED | 2025-11-04 | NCT07029568 |
| AstraZeneca | AZD4144 | — | COMPLETED | 2025-10-27 | NCT06675175 |
| Disc Medicine, Inc | DISC-0974 | — | COMPLETED | 2025-10-09 | NCT05745883 |
| Bayer | BAY3283142 | — | COMPLETED | 2025-02-24 | NCT06402721 |
| Biocodex | STIRIPENTOL oral administration | — | COMPLETED | 2024-11-30 | NCT05735951 |
| Bayer | BAY3283142 | — | COMPLETED | 2024-09-19 | NCT06487845 |
| Eli Lilly | LY3473329 | — | COMPLETED | 2024-09-06 | NCT05778864 |
| Novo Nordisk | Ziltivekimab | — | COMPLETED | 2024-06-12 | NCT05379829 |
| Eli Lilly | LY3502970 | — | COMPLETED | 2024-04-11 | NCT05936138 |
| AdAlta Limited | AD-214 | — | COMPLETED | 2024-02-09 | NCT05914909 |
| Incyte Corporation | INCB054707 | — | COMPLETED | 2024-02-07 | NCT05624723 |
| Eli Lilly | LY3819469 | — | COMPLETED | 2024-01-09 | NCT05841277 |
| Haisco Pharmaceutical Group Co., Ltd. | HSK21542 Injection | — | COMPLETED | 2023-11-21 | NCT06238388 |
| Boehringer Ingelheim | BI 425809 | — | COMPLETED | 2023-10-24 | NCT05718843 |
| Pharmicell Co., Ltd. | Cellgram-CKD | — | COMPLETED | 2023-09-21 | NCT05042206 |
| Eli Lilly | LY3437943 | — | COMPLETED | 2023-09-05 | NCT05611957 |
| Sunshine Lake Pharma Co., Ltd. | HEC53856 | — | COMPLETED | 2023-08-29 | NCT04925661 |
| Boehringer Ingelheim | BI 1015550 | — | COMPLETED | 2023-08-15 | NCT05718648 |
| Bayer | BAY3283142 | — | COMPLETED | 2023-07-19 | NCT05800444 |
| Incyte Corporation | INCB054707 | — | COMPLETED | 2023-06-30 | NCT05624710 |
| Bayer | Single oral dose of BAY3283142 IR (immediate release) tablet | — | COMPLETED | 2023-03-07 | NCT05515432 |
| Prokidney | Renal Autologous Cell Therapy (REACT) | — | COMPLETED | 2023-01-31 | NCT04115345 |
| Lisata Therapeutics, Inc. | CLBS201 | — | COMPLETED | 2023-01-26 | NCT04990427 |
| Bristol-Myers Squibb | Iberdomide | — | COMPLETED | 2023-01-23 | NCT04933747 |
| Sunshine Lake Pharma Co., Ltd. | HEC73077 tablets | — | COMPLETED | 2023-01-04 | NCT05492630 |
| Bayer | BAY3283142 | — | COMPLETED | 2023-01-03 | NCT05491642 |
| Nanogen Pharmaceutical Biotechnology Joint Stock Company | Stimus | — | COMPLETED | 2022-11-23 | NCT05636891 |
| AstraZeneca | cotadutide solution for injection | — | COMPLETED | 2022-09-12 | NCT05294458 |
| AN2 Therapeutics, Inc | Epetraborole | — | COMPLETED | 2022-06-10 | NCT05283746 |
| Zydus Lifesciences Limited | Desidustat | — | COMPLETED | 2022-03-27 | NCT04667533 |
| AstraZeneca | Zibotentan (Treatment A) | — | COMPLETED | 2021-10-22 | NCT04991571 |
| Pfizer | Aztreonam-Avibactam | — | COMPLETED | 2021-09-20 | NCT04486625 |
| AstraZeneca | Verinurad prolonged release HPMC capsule | — | COMPLETED | 2021-07-15 | NCT04550234 |
| VectivBio AG | Apraglutide | — | COMPLETED | 2021-07-05 | NCT04699032 |
| Eli Lilly | Pirtobrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2021-06-04 | NCT06190678 |
| Jiangsu HengRui Medicine Co., Ltd. | DDO-3055 | — | COMPLETED | 2021-05-11 | NCT03976115 |
| Rhythm Pharmaceuticals, Inc. | Setmelanotide | — | COMPLETED | 2021-04-17 | NCT04348175 |
| AstraZeneca | AZD5718 | — | COMPLETED | 2021-03-25 | NCT04734275 |
| Takeda | Azacitidine | Nucleoside Metabolic Inhibitor [EPC] | COMPLETED | 2021-03-19 | NCT03814005 |
| AstraZeneca | MEDI8367 | — | COMPLETED | 2021-01-03 | NCT04365218 |
| AstraZeneca | Verinurad | — | COMPLETED | 2020-11-23 | NCT04532918 |
| Boehringer Ingelheim | BI 764198 | — | COMPLETED | 2020-11-17 | NCT04176536 |
| Idorsia Pharmaceuticals Ltd. | ACT-541468 | — | COMPLETED | 2020-08-14 | NCT04024332 |
| Renibus Therapeutics, Inc. | RBT-9 | — | COMPLETED | 2020-07-31 | NCT04072861 |
| Akebia Therapeutics | Vadadustat | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | COMPLETED | 2020-05-05 | NCT03992066 |
| Renibus Therapeutics, Inc. | RBT-1 | — | COMPLETED | 2020-04-22 | NCT03893799 |
| Ensoma | MGTA-145 | — | COMPLETED | 2020-03-24 | NCT04154670 |
| Genfit | Elafibranor | Peroxisome Proliferator-activated Receptor Agonist [EPC] | COMPLETED | 2020-03-15 | NCT03844555 |
| Bayer | Copanlisib (ALIQOPA, BAY80-6946) | — | COMPLETED | 2020-03-13 | NCT03172884 |
| Jiangsu HengRui Medicine Co., Ltd. | DDO-3055 tablet | — | COMPLETED | 2020-01-18 | NCT04197778 |
| AstraZeneca | Verinurad ER8 capsule formulation (fasted) | — | COMPLETED | 2019-09-18 | NCT04024501 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2019-08-19 | NCT03482024 |
| Eli Lilly | Selpercatinib | Kinase Inhibitor [EPC] | COMPLETED | 2019-08-07 | NCT05469100 |
| DiaMedica Therapeutics Inc | DM199 | — | COMPLETED | 2019-07-21 | NCT03795389 |
| AstraZeneca | Verinurad | — | COMPLETED | 2019-04-26 | NCT03836599 |
| Renibus Therapeutics, Inc. | RBT-3 | — | COMPLETED | 2019-03-31 | NCT04072432 |
| Guerbet | P03277 | — | COMPLETED | 2019-02-01 | NCT03657784 |
| Amgen | Etelcalcetide | CaSR | COMPLETED | 2018-10-31 | NCT02833857 |
| Boehringer Ingelheim | BI 1467335 | — | COMPLETED | 2018-08-16 | NCT03302091 |
| Novartis | QAW039 | — | COMPLETED | 2018-08-07 | NCT03087942 |
| Merck | Midazolam oral solution | — | COMPLETED | 2018-08-02 | NCT03311841 |
| MedImmune LLC | MEDI0382 | — | COMPLETED | 2018-04-24 | NCT03235375 |
| Johnson & Johnson | Odalasvir | — | COMPLETED | 2018-04-09 | NCT02961660 |
| Bristol-Myers Squibb | CC-122 | — | COMPLETED | 2017-12-23 | NCT03097016 |
| Janssen Pharmaceutica N.V., Belgium | JNJ-64041575 | — | COMPLETED | 2017-12-06 | NCT03189498 |
| Merck | Gefapixant | — | COMPLETED | 2017-09-03 | NCT03108924 |
| Johnson & Johnson | AL-335 | — | COMPLETED | 2017-08-08 | NCT02894905 |
| Sarfez Pharmaceuticals, Inc. | Demadex 20mg Tablet | — | COMPLETED | 2017-07-20 | NCT03214874 |
| Taisho Pharmaceutical Co., Ltd. | TS-143 | — | COMPLETED | 2017-07-06 | NCT03581071 |
| Rockwell Medical Technologies, Inc. | Triferic | — | COMPLETED | 2017-07 | NCT02909153 |
| Bayer | BAY1841788 | — | COMPLETED | 2017-04-10 | NCT02894385 |
| KBP Biosciences | KBP-5074 | — | COMPLETED | 2016-12-20 | NCT02837237 |
| Akros Pharma Inc. | JTZ-951, 14C-JTZ-951 | — | COMPLETED | 2016-09 | NCT02805244 |
| Eli Lilly | LY3113593 | — | COMPLETED | 2016-06-22 | NCT02604160 |
| KBP Biosciences | KBP-5074 | — | COMPLETED | 2016-05-26 | NCT02653014 |
| Akros Pharma Inc. | JTZ-951 | — | COMPLETED | 2016-04 | NCT02581124 |
| Gilead | Selonsertib | — | COMPLETED | 2015-12-15 | NCT02509624 |
| Bayer | Molidustat(BAY85-3934) | — | COMPLETED | 2015-12-02 | NCT02312973 |
| Prolong Pharmaceuticals | SANGUINATE | — | COMPLETED | 2015-11-18 | NCT02437422 |
| Eli Lilly | LY2928057 | — | COMPLETED | 2015-10 | NCT01991483 |
| Amgen | Cinacalcet | — | COMPLETED | 2015-09-23 | NCT01290029 |
| Intarcia Therapeutics | ITCA 650 (Exenatide in osmotic mini pump) | — | COMPLETED | 2015-07 | NCT02320045 |
| Fuji Yakuhin Co., Ltd. | FYU-981, (Oral single dosing) | — | COMPLETED | 2015-03 | NCT02347046 |
| Jiangsu HengRui Medicine Co., Ltd. | SP2086 | — | COMPLETED | 2015-01 | NCT02815774 |
| Boehringer Ingelheim | Afatinib healthy | — | COMPLETED | 2014-12 | NCT02096718 |
| Astellas Pharma Inc | ASP3325 | — | COMPLETED | 2014-11-04 | NCT02510274 |
Novel Drugs by Company (New molecular entities)
AKEBIA 1 drug
Reformulations (17 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
FUROSCIX
SCPHARMACEUTICALS
T3 2022
KERENDIA
Bayer
T1 2021
MONOFERRIC
PHARMACOSMOS
T5 2020
RETACRIT
Pfizer
T5 2018
SYNJARDY XR
Boehringer Ingelheim
T3 2016
RAYALDEE
EIRGEN
T5 2016
SYNJARDY
Boehringer Ingelheim
T4 2015
XIGDUO XR
AstraZeneca
T4 2014
AURYXIA
KERYX BIOPHARMS
T5 2014
JARDIANCE
Boehringer Ingelheim
T1 2014
FARXIGA
AstraZeneca
T1 2014
VELPHORO
VIFOR FRESENIUS
T5 2013
INJECTAFER
AM REGENT
T5 2013
FERAHEME
AZURITY
T2 2009
RENVELA
Sanofi
T3 2007
FERRLECIT
Sanofi
T1 1999
ZEMPLAR
AbbVie
T1 1998
Drug Targets
Generic Drugs (5 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs